Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity Article

publication date

  • July 5, 2022

webpage

published in

keywords

  • Psoriasis
  • biologic therapy
  • biologics
  • comorbid disease
  • metabolic disease
  • multimorbidity
  • outcomes
  • psoriatic disease
  • treatment response